Edmund Moon
Overview
Explore the profile of Edmund Moon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao Y, Moon E, Carpenito C, Paulos C, Liu X, Brennan A, et al.
Cancer Res
. 2024 Nov;
84(21):3702.
PMID: 39492678
No abstract available.
2.
Thompson J, Aggarwal C, Wong J, Nimgaonkar V, Hwang W, Andronov M, et al.
JTO Clin Res Rep
. 2022 Apr;
3(4):100301.
PMID: 35392653
Introduction: The availability of targeted therapies has transformed the management of advanced NSCLC; however, most patients do not undergo guideline-recommended tumor genotyping. The impact of plasma-based next-generation sequencing (NGS) performed...
3.
Geuijen C, Tacken P, Wang L, Klooster R, van Loo P, Zhou J, et al.
Nat Commun
. 2021 Jul;
12(1):4445.
PMID: 34290245
Immune checkpoint inhibitors demonstrate clinical activity in many tumor types, however, only a fraction of patients benefit. Combining CD137 agonists with these inhibitors increases anti-tumor activity preclinically, but attempts to...
4.
Martinez M, Kim S, St Jean N, OBrien S, Lian L, Sun J, et al.
Oncoimmunology
. 2021 Feb;
10(1):1873607.
PMID: 33537176
PD1 blockade to reinvigorate T cells has become part of standard of care for patients with NSCLC across disease stages. However, the majority of patients still do not respond. One...
5.
Haas A, Tanyi J, OHara M, Gladney W, Lacey S, Torigian D, et al.
Mol Ther
. 2019 Aug;
27(11):1919-1929.
PMID: 31420241
This phase I study investigated the safety and activity of lentiviral-transduced chimeric antigen receptor (CAR)-modified autologous T cells redirected against mesothelin (CART-meso) in patients with malignant pleural mesothelioma, ovarian carcinoma,...
6.
Kimura T, Monslow J, Klampatsa A, Leibowitz M, Sun J, Liousia M, et al.
Am J Physiol Lung Cell Mol Physiol
. 2019 Jun;
317(2):L271-L282.
PMID: 31188013
Fibroblast activation protein (FAP), a cell surface serine protease, is upregulated on a subset of activated fibroblasts (often distinct from α-smooth muscle actin-expressing myofibroblasts) associated with matrix remodeling, including fibroblasts...
7.
Newick K, OBrien S, Moon E, Albelda S
Annu Rev Med
. 2016 Nov;
68:139-152.
PMID: 27860544
The field of cancer immunotherapy has been re-energized by the application of chimeric antigen receptor (CAR) T cell therapy in cancers. These CAR T cells are engineered to express synthetic...
8.
Antonia S, Vansteenkiste J, Moon E
Am Soc Clin Oncol Educ Book
. 2016 Jun;
35:e450-8.
PMID: 27249753
Advanced-stage non-small cell lung cancer (NSCLC) and small cell lung cancer are cancers in which chemotherapy produces a survival benefit, although it is small. We now know that anti-PD-1/PD-L1 has...
9.
Newick K, Moon E, Albelda S
Mol Ther Oncolytics
. 2016 May;
3:16006.
PMID: 27162934
Chimeric antigen receptor (CAR) T cells are engineered constructs composed of synthetic receptors that direct T cells to surface antigens for subsequent elimination. Many CAR constructs are also manufactured with...
10.
Newick K, OBrien S, Sun J, Kapoor V, Maceyko S, Lo A, et al.
Cancer Immunol Res
. 2016 Apr;
4(6):541-51.
PMID: 27045023
Antitumor treatments based on the infusion of T cells expressing chimeric antigen receptors (CAR T cells) are still relatively ineffective for solid tumors, due to the presence of immunosuppressive mediators...